# Proposed Rule to Establish Cannabis Research Infrastructure in Missouri > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/2026-cannabis-research-infrastructure-missouri/ > **Published:** 2026-04-13T23:05:35-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:22:35-04:00 > **Clinical Summary:** Explore the 2026 cannabis research infrastructure proposal in Missouri enabling dedicated marijuana research facilities and advancing medical cannabis studies. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Research InfrastructureClinical Evidence[State Policy](https://cedclinic.com/will-the-coronavirus-force-states-to-legalize-marijuana/)Medical CannabisRegulatory Framework Why This Matters Dedicated research facilities represent a critical infrastructure need for advancing [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) beyond the current patchwork of limited academic studies. Missouri’s regulatory framework could serve as a model for other states seeking to balance research access with appropriate oversight. Clinical Summary Missouri is proposing regulations that would establish dedicated marijuana research facilities, potentially expanding beyond traditional academic settings. This regulatory development follows the state’s medical cannabis program and reflects growing recognition that robust [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) requires appropriate infrastructure. The proposed framework would likely include oversight mechanisms while facilitating access to standardized cannabis products for research purposes. Such facilities could accelerate studies on dosing, formulations, and clinical applications that are currently limited by federal restrictions and supply chain challenges. Dr. Caplan’s Take “This is exactly what [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) needs — proper research infrastructure with regulatory clarity. Too many of my clinical decisions are still based on incomplete data because we lack the facilities to conduct the studies that would inform evidence-based practice.” Clinical Perspective 🧠 Clinicians should monitor how these research facilities develop standardized protocols and outcome measures that could inform practice guidelines. The quality and reproducibility of research from such facilities will depend heavily on their regulatory oversight and methodological rigor. This development may eventually provide the clinical evidence base that both physicians and patients need for more confident therapeutic decisions. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Proposed%20rule%20would%20allow%20for%20creation%20of%20marijuana%20research%20facilities%20in%20Misso...%20%40drcaplan&url=https%3A//www.missourinet.com/2026/04/13/proposed-rule-would-allow-for-creation-of-marijuana-research-facilities-in-missouri/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.missourinet.com/2026/04/13/proposed-rule-would-allow-for-creation-of-marijuana-research-facilities-in-missouri/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Proposed%20rule%20would%20allow%20for%20creation%20of%20marijuana%20research%20facilities%20in%20Misso...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.missourinet.com/2026/04/13/proposed-rule-would-allow-for-creation-of-marijuana-research-facilities-in-missouri/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.missourinet.com/2026/04/13/proposed-rule-would-allow-for-creation-of-marijuana-research-facilities-in-missouri/](https://www.missourinet.com/2026/04/13/proposed-rule-would-allow-for-creation-of-marijuana-research-facilities-in-missouri/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis research?](#What_is_the_clinical_relevance_rating_for_this_cannabis_research) - [What areas does this cannabis research cover?](#What_areas_does_this_cannabis_research_cover) - [Why is this classified as “emerging findings”?](#Why_is_this_classified_as_8220emerging_findings8221) - [What type of healthcare professionals should pay attention to this research?](#What_type_of_healthcare_professionals_should_pay_attention_to_this_research) - [How does this research relate to current medical cannabis practice?](#How_does_this_research_relate_to_current_medical_cannabis_practice) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis research? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the findings represent emerging developments or policy changes that healthcare professionals should monitor closely. #### What areas does this cannabis research cover? The research encompasses multiple key areas including research infrastructure, clinical evidence, [state policy](https://cedclinic.com/will-the-coronavirus-force-states-to-legalize-marijuana/), and medical cannabis applications. This interdisciplinary approach indicates comprehensive coverage of cannabis-related healthcare topics. #### Why is this classified as “emerging findings”? The article is marked as “New” and falls under the category of emerging findings worth monitoring closely. This suggests the research presents recent developments that may influence future clinical practice or policy decisions. #### What type of healthcare professionals should pay attention to this research? Given the clinical relevance rating and medical cannabis focus, this research is particularly relevant for physicians, nurse practitioners, and other healthcare providers involved in cannabis medicine. The policy components also make it important for healthcare administrators and policy makers. #### How does this research relate to current medical cannabis practice? This research appears to bridge clinical evidence with state policy and research infrastructure, suggesting it may impact how medical cannabis is prescribed, regulated, or studied. The notable clinical interest rating indicates potential implications for current medical cannabis protocols. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [US: Proposed rule would create cannabis research facilities in Missouri](https://cedclinic.com/cannabis-research-facilities-missouri-proposed-rule/) An overview of the US proposed regulations to establish [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) facilities in Missouri, highlighting potential impacts on clinical studies. [Read More](https://cedclinic.com/cannabis-research-facilities-missouri-proposed-rule/) [Trump’s reclassification move on marijuana could boost medical research – C&EN](https://cedclinic.com/cannabis-schedule-i-reclassification-research-impact/) Analysis of how federal marijuana reclassification efforts may enhance [medical cannabis research](https://cedclinic.com/cannabis-varieties-differentiation-cannabinomics/) opportunities nationwide. [Explore Insights](https://cedclinic.com/cannabis-schedule-i-reclassification-research-impact/) [State of Texas: Marijuana reclassification could expand medical research – Yahoo](https://cedclinic.com/texas-marijuana-reclassification-expand-medical-research/) Discussion on how marijuana reclassification in Texas might expand medical research infrastructure and clinical studies. [Learn More](https://cedclinic.com/texas-marijuana-reclassification-expand-medical-research/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).